PRA Health Sciences Inc (PRAH), which is a top contract research organization (CRO), had some challenges when it pulled off its IPO in mid-November. The company priced the offering at $18, which was below the expected range of $20 to $23. But things have improved since then, as PRA stock is up about 18% from its IPO price.
Here’s why investors should expect more on the upside from PRAH stock.
Founded more than 30 years ago, PRA Health Sciences is a top provider of outsourced clinical trial services for biotech and pharmaceutical industries. Read